Advertisement Pharmaceutical Business review - Page 695 of 5279 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 30, 2026

Zymeworks agrees to buy Theravance Biopharma for $929m

Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m (C$1.32bn).

Zymeworks will be entitled to 20% of the proceeds from ampreloxetine. Credit: JHVEPhoto/Shutterstock.com.